שווי פעילות לרווח לפני ריבית, מסים ופחת Quoin Pharma (QNRX)

Quoin Pharmaceuticals is establishing strategic alliances with specialized funds to combat hereditary dermatoses, including Netherton syndrome. The unique therapeutic environment they have created ensures full patient loyalty and a seven-year FDA monopoly. The development of proprietary topical agents is based on extensive R&D research into small molecules. This chart of the current share price reflects an EV/EBITDA ratio of 0.00.

EV/EBITDA determines the business value including debt relative to operating profit, allowing for an assessment of the asset's real price without the influence of the tax regime. For Quoin Pharmaceuticals (QNRX), this ratio reflects the capitalization of unique patents in rare skin disease therapy and the dependence of clinics on their supplies. Analyzing the historical EV/EBITDA trajectory helps identify stock overvaluation when market optimism outpaces actual earnings growth.